Friday 6 November 2026
Export ZBH’s income statement to Excel — free account
Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.
- Revenue
- +3.07%
- EPS
- −13.5%
- Free cash flow
- +29.8%
- Total debt
- −7.50%
Quarter to September 2026, against a year earlier
105.79
1.06
−0.99%
Follow ZBH
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.36 | 20.85 | 23.36 | 25.19 |
+8 more quarters Free account |
P/S ratio |
1.97 | 1.94 | 2.10 | 2.16 | |
P/FCF ratio |
15.16 | 15.96 | 17.49 | 16.53 | |
P/Operating CF |
30.22 | 36.95 | 49.06 | 34.41 | |
P/B ratio |
1.34 | 1.31 | 1.39 | 1.40 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.80 | 2.78 | 2.93 | 3.00 | |
EV/EBITDA |
10.59 | 10.21 | 10.78 | 11.28 | |
EV/Operating CF |
12.75 | 13.55 | 14.75 | 14.57 | |
EV/FCF |
21.53 | 22.78 | 24.48 | 22.96 | |
Quick Ratio |
0.63 | 0.72 | 0.75 | 0.89 | |
Current Ratio |
1.46 | 1.69 | 1.73 | 1.98 | |
Net Debt/EBITDA |
0.00 | 11.84 | 10.96 | 15.80 | |
Debt/Assets |
31.88% | 32.81% | 32.88% | 32.56% | |
Debt/Equity |
0.59 | 0.59 | 0.59 | 0.59 | |
Asset Turnover |
0.36 | 0.37 | 0.37 | 0.37 | |
Operating CF/Net income |
2.92 | 2.26 | 1.51 | 3.71 | |
Capex/Depreciation |
(0.75) | (0.75) | (0.56) | (0.71) | |
Interest Coverage |
4.11 | 4.47 | 5.42 | 2.15 | |
Research and Development Expense of Revenue |
5.13% | 4.81% | 4.96% | 5.29% | |
Selling, General and Administrative Expense of Revenue |
41.45% | 41.31% | 40.73% | 38.87% | |
Intangible Assets out of Total Assets |
0.64 | 0.63 | 0.64 | 0.64 | |
Share Based Compensation of Revenue |
1.17% | 1.13% | 1.16% | 1.07% | |
Graham Net Nets |
(0.34) | (0.31) | (0.29) | (0.30) | |
Graham Number |
0.00 | 78.15 | 75.25 | 71.79 | |
Earnings Yield |
4.47% | 4.80% | 4.28% | 3.97% | |
Free Cash Flow Yield |
6.60% | 6.26% | 5.72% | 6.05% | |
Revenue per Share |
10.83 | 11.33 | 10.70 | 11.33 | |
Operating CF per Share |
2.94 | 2.33 | 1.84 | 2.61 | |
Capex per Share |
(1.12) | (1.05) | (0.78) | (1.02) | |
Free Cash Flow per Share |
1.82 | 1.28 | 1.06 | 1.60 | |
Cash per Share |
2.10 | 2.13 | 2.18 | 2.99 | |
Shareholders Equity per Share |
66.80 | 65.73 | 65.03 | 64.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
66.80 | 65.73 | 65.03 | 64.17 | |
Free Cash Flow |
347.40 | 246.00 | 206.90 | 315.90 | |
Working Capital |
1,626.60 | 2,083.20 | 2,098.20 | 2,536.20 | |
Capital Expenditures |
(212.60) | (201.80) | (152.50) | (201.50) | |
Net Current Asset Value |
(5,684.00) | (5,068.60) | (5,077.50) | (5,266.10) | |
EV/EBIT |
20.69 | 19.60 | 20.93 | 22.52 | |
Capex to Sales |
0.10 | 0.09 | 0.07 | 0.09 | |
Price to Operating Income |
14.57 | 13.73 | 14.96 | 16.21 | |
| Other line items | |||||
Average Receivables |
1,707.15 | 1,690.40 | 1,631.00 | 1,592.55 | |
Average Payables |
336.40 | 350.55 | 331.25 | 248.80 | |
Average Inventory |
2,425.45 | 2,362.25 | 2,245.50 | 2,260.85 | |
Average Assets |
23,513.30 | 22,831.45 | 22,452.75 | 22,228.50 | |
Average Common Equity |
12,745.80 | 12,583.45 | 12,542.65 | 12,591.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026